Research that is free to access for all investors. Companies commission these providers to write research about them.
Brokers who write research on their corporate clients and make it available through our main bundle offering.
Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.
Event in Progress:
Discover the latest content that has just been published on Research Tree
The Q3 results fell somewhat short of the street’s expectations, although both the segments saw healthy growth. Meanwhile, the management narrowed its full-year guidance to which the markets expressed their disappointment. Nonetheless, Alcon’s medium-to-long term prospects remain promising, on the back of its dominant position in both segments, material unmet eye care needs across the globe and the ongoing profitability improvements.
Companies: Alcon AG
AlphaValue
The Q2 23 beat was driven by healthy performances from both business segments, and the top-line benefits also percolated down to operating profitability. Moreover, the management upgraded its 2023 guidance. Overall, Alcon’s commanding position in its target markets, promising growth prospects for its offerings and improving profitability all support our positive recommendation.
2023 has started on a strong note, driven by robust performances from both divisions. Even the full-year guidance has been upgraded and, while the management has factored recessionary pressures into its outlook, one cannot rule out another guidance uptick in the event that these pressures are less severe than anticipated. Overall, we reiterate our positive recommendation on Alcon, given its dominant position and consistent outperformance vs. the target markets, together with the ongoing profitab
The Q4 results were driven by healthy performances from both segments, although the dividends was lower than expected. Nonetheless, the 2023 guidance was favourable, pointing to decent top-line growth and the continuation of ‘core’ margin improvements. Overall, Alcon’s strong positioning in its target markets, healthy growth prospects and ongoing profitability improvements underpin our positive recommendation. Also, the upside is supported by the fact that the current relative valuation levels a
The healthy growth trajectory of the last few quarters was maintained in Q3, and as a result, the 2022 guidance in CER growth terms was improved slightly. However, considering the FX headwinds, the guidance, in absolute terms, was moderated. The firm also announced an additional cost-savings plan to fight the challenging macroeconomic environment. Overall, Alcon remains well-positioned to benefit from a dominant position in its markets and a healthy balance sheet – aiding newer growth initiative
Alcon’s Q2 results were in line with our expectations. In Q2, growth was driven by the post-Covid recovery in its target markets and the strength of the portfolio. However, the group revised downwards its full-year outlook due to tough external challenges i.e., adverse FX, spiralling inflation and supply chain challenges. Having said that, our positive outlook on the Swiss giant is reiterated given the group’s dominance in the target markets and the fact that the above challenges are mostly exog
Alcon has started 2022 on a good note, with continued strong growth momentum being witnessed across the segments. While spiralling inflation and FX headwinds, due to rising geopolitical crisis and the worsening Covid-19 situation in China are troublesome, fortunately the Swiss giant has been able to absorb most of the shock by acting swiftly. This has also been reflected in the maintained 2022 outlook despite all the challenges. Hence, our positive stance is reiterated.
Alcon finished 2021 on a high, with strong growth across segments. Moreover, 2022 is guided to be another solid year, which, apart from the strength in its focus areas, should also benefit from the continued recovery in the global ophthalmology market. While ongoing inflationary headwinds and the increase in operating expenses do pose some challenges, the group is confident of successfully mitigating them. Our positive recommendation is reiterated.
Alcon has witnessed a strong 2021, with a healthy performance across (sub-)segments. While eye care markets continue to recover at a varied pace across different regions, the group still delivered impressive results, driven by its robust product portfolio. Although the Omicron variant concerns are likely to result in some near-term moderation, it is not expected to have any major bearing on the group’s longer term fortunes. Hence, our positive stock recommendation is reinforced.
Alcon posted strong results in Q2, driven by robust growth momentum across the segments. While returning demand for eye-care (elective) surgeries drove the Surgical’s segment, the robust uptake for new products bolstered Vision Care. Driven by the solid US market trends (backed by a strong Q2), the group has upgraded its full-year outlook. While resurfacing Delta variant concerns could play spoilsport, management is confident that it is past the worst of the pandemic.
Alcon posted decent Q1 results driven by a strong performance in Surgical – the recovery in elective surgeries bolstered growth for consumables. However, Vision Care was weak as the previous year’s panic stocking played spoilsport. Seasonally weak Q2 is expected to be soft and the group’s H2 21 recovery largely hinges upon an improvement in the pandemic situation. Profitability could also come under pressure for the remainder of the year due to additional promotion efforts and the creation of a
Alcon revealed promising mid-term financial targets at its 2021 CMD. Sales momentum is set to accelerate – driven by increasing market penetration and new product launches in both segments – and the group is on track to outgrow the market. Importantly, steady margin expansion is also on the cards and along with the normalisation of capex should drive sustainable shareholder rewards. Thus, Alcon could be an attractive ophthalmology play for the post-pandemic world.
Benefiting from new product launches and improving ophthalmic market conditions, both the Surgery and Vision care segments returned to growth in Q4 20. In our view, the recently-introduced products (Vivity, Precision1 for Astigmatism and Pataday), along with the geographic expansion of PanOptix and Prescision1, should bolster the top line in the mid-term. Moreover, the favourable product mix and cost-cutting should result in sustained operating margin expansion. Nonetheless, the uncertainty arou
Alcon, a dominant force in the $25bn ophthalmology space, is set to outgrow the industry in the mid-term – driven by the pick-up in demand for recently-launched products, PanOptix and Precision1. Moreover, with robust margin expansion potential – led by an improving product mix and targeted cost-savings – earnings should grow healthily. A sturdy balance sheet increases its appeal further. Interestingly, Alcon is recovering faster than rivals from the COVID-19-hiccups and its sales and profitabil
Research Tree provides access to ongoing research coverage, media content and regulatory news on Alcon AG. We currently have 0 research reports from 4 professional analysts.
Companies: CNC RNO MAI IUG CUSN POLB
Cavendish
Companies: STX FADL POLB
Poolbeg Pharma has announced FY 2023 results to end December 2023, which positively reflect the company’s capital-efficient operating model with net cash of £12.2m being reported, significantly ahead of our expectations (2023E: £10.9m). Meaningful R&D progress whilst maintaining financial prudence means that Poolbeg enters 2024 with a strong balance sheet in absolute terms and relative to many biotech peers, with a cash runway (to fund the existing R&D pipeline) we forecast will extend into 2026
Companies: Poolbeg Pharma PLC
Companies: Inspiration Healthcare Group PLC
Liberum
Companies: Warpaint London PLC
Shore Capital
1st May 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: REDX Pharma (REDX.L) has delisted from the AIM Market What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing
Companies: TXP CNC RNO MAI ANX IUG CUSN POLB
Hybridan
Companies: 88E CNC FTC TRCS HEIQ CREO ZAM
Companies: Destiny Pharma Plc
26th April 2024 A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: C4X Discovery Holdings (C4XD.L) has left AIM. What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acqu
Companies: ROQ SOU PRM ITM THRU LGRS KIBO ADF
Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our web
Companies: Shield Therapeutics Plc
Edison
Companies: TheraCryf PLC (TCF:LON)Poolbeg Pharma PLC (POLB:LON)
Creo Medical has presented real-world evidence of the economic utility of its minimally invasive electrosurgical devices, based on NHS data from 130 submucosal dissection procedures using Creo’s flagship Speedboat Inject device. The data demonstrated net cash savings of £687k for the NHS trust, driven by a significant reduction in both hospitalisation and critical care costs. We believe this provides external validation to Creo’s pursuit of improving patients’ outcomes through its novel suite of
Companies: Creo Medical Group Plc
FY23 was a transitional year for Biodexa, following the restructuring announced in March 2023 into a therapeutic company from a drug delivery specialist, and the implementation of cost-saving initiatives in light of the macroeconomic environment. The pipeline expansion primarily de-risks the business, partially fulfilled with the acquisition of lyn kinase activator tolimidone, for type 1 diabetes (T1D), in late 2023. Management estimates gross cash of £5.97m at end-FY23 to provide a runway into
Companies: Biodexa Pharmaceuticals plc Sponsored ADR
30th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: Wincanton (WIN.L) has left the Premium list of the Main Market Byotrol (BYOT.L) has left the AIM Market What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admis
Companies: KOO CLCO TRT AVCT KIBO POLB
Futura Medical’s investment case has shifted firmly onto commercial execution. The highly successful initial launches of Eroxon, its novel topical gel for ED (erectile dysfunction), by partner Cooper Consumer Health in the UK and Belgium are now being followed by roll-outs across the major European markets. The much-anticipated launch in the commercially important US market by consumer healthcare giant Haleon is expected before February 2025. Launches in Other Regions are anticipated throughout
Companies: Futura Medical plc
Trinity Delta
Share: